Search

Your search keyword '"Kulke, M"' showing total 257 results
Start Over Author "Kulke, M"
257 results on '"Kulke, M"'

51. SP-0570: Neuroendocrine tumours - personalised diagnosis and treatment using radiolabelled peptides

Author

Baum, R.P., primary, Strosberg, J., additional, Wolin, E., additional, Chasen, B., additional, Kulke, M., additional, Bushnell, D., additional, Caplin, M., additional, Hobday, T., additional, Hendifar, A., additional, Oberg, K., additional, Lopera Sierra, M., additional, Kwekkeboom, D., additional, Ruszniewsk, P., additional, Krenning, E., additional, and Mittra, E., additional

Published
2016
Full Text
View/download PDF

52. 5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study

Author

Yao, J., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Raderer, M., Lahner, Harald, Voi, M., Pacaud, L., Lincy, J., Sachs, C., Valle, J., Delle Fave, G., Van Cutsem, E., Tesselaar, M. E. T., Shimada, Y., Oh, D. Y., Strosberg, J., Kulke, M. H., Pavel, M. E., and RADIANT-4 Study Grp

Subjects
Cancer Research, medicine.medical_specialty, Pathology, Everolimus, Lung, business.industry, Medizin, Neuroendocrine tumors, medicine.disease, Placebo, Gastroenterology, Double blind, medicine.anatomical_structure, Oncology, Internal medicine, medicine, business, medicine.drug
Published
2015
Full Text
View/download PDF

55. Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial)

Author

Kulke, M. H., Hoersch, D., Caplin, M., Anthony, L., Bergsland, E., Öberg, Kjell, Welin, Staffan, Warner, R., Lombard-Bohas, C., Kunz, P., Grande, E., Valle, J., Fleming, D., Lapuerta, P., Banks, P., Jackson, S., Wheeler, D., Zambrowicz, B., Sands, A., Pavel, M., Kulke, M. H., Hoersch, D., Caplin, M., Anthony, L., Bergsland, E., Öberg, Kjell, Welin, Staffan, Warner, R., Lombard-Bohas, C., Kunz, P., Grande, E., Valle, J., Fleming, D., Lapuerta, P., Banks, P., Jackson, S., Wheeler, D., Zambrowicz, B., Sands, A., and Pavel, M.

Abstract

Meeting Abstract: 37LBA

Published
2015

56. 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours : Results of the phase III NETTER-1 trial

Author

Strosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Caplin, M., Baum, R. P., Mittra, E., Hobday, T., Hendifar, A., Öberg, Kjell, Sierra, M. Lopera, Ruszniewski, P., Kwekkeboom, D., Strosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Caplin, M., Baum, R. P., Mittra, E., Hobday, T., Hendifar, A., Öberg, Kjell, Sierra, M. Lopera, Ruszniewski, P., and Kwekkeboom, D.

Abstract

Meeting Abstract: 6LBA

Published
2015

57. 6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial

Author

Strosberg, J., primary, Wolin, E., additional, Chasen, B., additional, Kulke, M., additional, Bushnell, D., additional, Caplin, M., additional, Baum, R.P., additional, Mittra, E., additional, Hobday, T., additional, Hendifar, A., additional, Oberg, K., additional, Lopera Sierra, M., additional, Ruszniewski, P., additional, and Kwekkeboom, D., additional

Published
2015
Full Text
View/download PDF

58. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

Author

Zurita, A J, primary, Khajavi, M, additional, Wu, H-K, additional, Tye, L, additional, Huang, X, additional, Kulke, M H, additional, Lenz, H-J, additional, Meropol, N J, additional, Carley, W, additional, DePrimo, S E, additional, Lin, E, additional, Wang, X, additional, Harmon, C S, additional, and Heymach, J V, additional

Published
2015
Full Text
View/download PDF

59. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors

Author

Kos Kudła, B, O'Toole, D, Falconi, Massimo, Gross, D, Klöppel, G, Sundin, A, Ramage, J, Oberg, K, Wiedenmann, B, Komminoth, P, Van Custem, E, Mallath, M, Papotti, M, Caplin, M, Arnold R, Palma de Mallorca Consensus Conference P. a. r. t. i. c. i. p. a. n. t. s., Buscombe, J, Chen, Yj, Cioppi, F, de Herder, W, Eriksson, B, Fazio, N, Grossman, A, Kaltsas, G, Kianmanesh, R, Kulke, M, Kwekkeboom, D, Lebtahi, R, Lesurtel, M, Lind, P, Lopes, Jm, Nilsson, O, O'Connor, J, Pape, Uf, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Sasano, H, Scoazec, Jy, Sevilla Garcia, I, Steinmüller, T., Kos Kudła, B, O'Toole, D, Falconi, Massimo, Gross, D, Klöppel, G, Sundin, A, Ramage, J, Oberg, K, Wiedenmann, B, Komminoth, P, Van Custem, E, Mallath, M, Papotti, M, and Caplin, M.

Subjects
medicine.medical_specialty, Pathology, Lung Neoplasms, Endocrinology, Diabetes and Metabolism, Lung metastasis, MEDLINE, Bone Neoplasms, Digestive System Neoplasms, Humans, Neuroendocrine Tumors, Neuroendocrine tumors, Cellular and Molecular Neuroscience, Endocrinology, Internal medicine, medicine, Lung, Endocrine and Autonomic Systems, business.industry, Respiratory disease, Cancer, respiratory system, medicine.disease, respiratory tract diseases, medicine.anatomical_structure, Lung disease, business
Abstract

ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors

Published
2010

60. ENETS consensus guidelines for the management of patients with rare metastases from digestive neuroendocrine tumors: rationale and working framework. Introduction

Author

O'Toole, D, Rindi, G, Plã¶ckinger, U, Wiedenmann, B, Collaborators: Arnold, R, Buscombe, J, Caplin, M, Chen, Yj, Cioppi, F, de Herder, W, Eriksson, B, Falconi, Massimo, Fazio, N, Gross, D, Grossman, A, Kaltsas, G, Kianmanesh, R, Kloppel, G, Komminoth, P, Kos Kuda, B, Kulke, M, Kwekkeboom, D, Lebtahi, R, Lesurtel, M, Lind, P, Lopes, Jm, Mallath, M, Nikou, G, Nilsson, O, Oberg, K, O'Connor, J, Pape, Uf, Papotti, M, Pavel, M, Perren, A, Ploeckinger, U, Ramage, J, Ruszniewski, P, Sasano, H, Scoazec, Jy, Sevilla Garcia, I, Steinmuller, T, Sundin, A, Van Cutsem, E, O'Toole, D., O'Toole, D, Rindi, G, Plöckinger, U, Wiedenmann, B, Enets, Collaborator, and Falconi, Massimo

Subjects
medicine.medical_specialty, Endocrine and Autonomic Systems, business.industry, Consensus Development Conferences as Topic, Endocrinology, Diabetes and Metabolism, Guidelines as Topic, Neuroendocrine tumors, Digestive System Neoplasms, medicine.disease, Humans, Neoplasm Metastasis, Neuroendocrine Tumors, Cellular and Molecular Neuroscience, Endocrinology, Internal medicine, medicine, business
Published
2010

61. ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors

Author

Pavel, M, Grossman, A, Arnold, R, Perren, A, Kaltsas, G, Steinmüller, T, de Herder, W, Nikou, G, Plöckinger, U, Lopes, Jm, Sasano, H, Buscombe, J, Lind, P, O'Toole, D, Oberg, K, Collaborators: Caplin M, Palma de Mallorca Consensus Conference P. a. r. t. i. c. i. p. a. n. t. s., Chen, Yj, Cioppi, F, Eriksson, B, Falconi, M, Fazio, N, Gross, D, Kianmanesh, R, Komminoth, Gp, Kos Kudła, B, Kulke, M, Kwekkeboom, D, Lebtahi, R, Lesurtel, M, Mallath, M, Nilsson, O, O'Connor, J, Pape, Uf, Papotti, Mauro Giulio, Ramage, J, Rindi, G, Ruszniewski, P, Scoazec, Jy, Sevilla Garcia, I, Sundin, A, Van Cutsem, E, Wiedenmann, B., Erasmus MC other, Internal Medicine, M, Pavel, A., Grossman, R., Arnold, A., Perren, G., Kaltsa, T., Steinmüller, W. d., Herder, G., Nikou, U., Plöckinger, J. M., Lope, H., Sasano, J., Buscombe, P., Lind, D., O'Toole, K., Oberg, and Falconi, Massimo

Subjects
endocrine system, medicine.medical_specialty, Pathology, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Brain Neoplasms, Digestive System Neoplasms, Female, Heart Neoplasms, Humans, Neuroendocrine Tumors, Ovarian Neoplasms, Ovary, Neuroendocrine tumors, Metastasis, Cellular and Molecular Neuroscience, Heart neoplasms, Endocrinology, Internal medicine, medicine, Endocrine and Autonomic Systems, business.industry, Cancer, medicine.disease, female genital diseases and pregnancy complications, ddc, medicine.anatomical_structure, cardiovascular system, business
Abstract

ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors

Published
2010
Full Text
View/download PDF

63. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

Author

Kulke, M. H., Ruszniewski, P., Van Cutsem, E., Lombard-Bohas, C., Valle, J. W., De Herder, W. W., Pavel, M., Degtyarev, E., Brase, J. C., Bubuteishvili-Pacaud, L., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, R. P., and Yao, J. C.

Subjects
*EVEROLIMUS, *SOMATOSTATIN, *NEUROENDOCRINE tumors, *DRUG efficacy, *MEDICATION safety, *MTOR inhibitors, *TUMOR treatment
Abstract

Background: Several studies have demonstrated the antitumor activity of first-generation somatostatin analogs (SSAs), primarily targeting somatostatin receptor (sstr) subtypes 2 and 5, in neuroendocrine tumors (NET). Pasireotide, a second-generation SSA, targets multiple sstr subtypes. We compared the efficacy and safety of pasireotide plus everolimus to everolimus alone in patients with advanced, well-differentiated, progressive pancreatic NET. Patients and methods: Patients were randomized 1 : 1 to receive a combination of everolimus (10 mg/day, orally) and pasireotide long-acting release (60 mg/28 days, intramuscularly) or everolimus alone (10 mg/day, orally); stratified by prior SSA use, and baseline serum chromogranin A and neuron-specific enolase. The primary end point was progression-free survival (PFS). Secondary end points included overall survival, objective response rate, disease control rate, and safety. Biomarker response was evaluated in an exploratory analysis. Results: Of 160 patients enrolled, 79 were randomized to the combination arm and 81 to the everolimus arm. Baseline demographics and disease characteristics were similar between the treatment arms. No significant difference was observed in PFS: 16.8months in combination arm versus 16.6months in everolimus arm (hazard ratio, 0.99; 95% confidence interval, 0.64-1.54). Partial responses were observed in 20.3% versus 6.2% of patients in combination arm versus everolimus arm; however, overall disease control rate was similar (77.2% versus 82.7%, respectively). No significant improvement was observed inmedian overall survival. Adverse events were consistent with the known safety profile of both the drugs; grade 3 or 4 fasting hyperglycemia was seen in 37% versus 11% of patients, respectively. Conclusions: The addition of pasireotide to everolimus was not associated with the improvement in PFS compared with everolimus alone in this study. Further studies to delineate mechanisms by which SSAs slow tumor growth in NET are warranted. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

64. Ph Ii Study of Bez235 in Patients with Advanced Pancreatic Neuroendocrine Tumors (Pnet) After Mtor Inhibitor Therapy Failure: Stage I Interim Results

Author

Fazio, N., primary, Buzzoni, R., additional, Baudin, E., additional, Antonuzzo, L., additional, Hubner, R., additional, Lahner, H., additional, De Herder, W.W., additional, Raderer, M., additional, Teule, A., additional, Capdevila, J., additional, Libutti, S., additional, Kulke, M., additional, Shah, M., additional, Dey, D., additional, Turri, S., additional, Aimone, P., additional, and Verslype, C., additional

Published
2014
Full Text
View/download PDF

66. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide

Author

Kulke, M. H., primary, O'Dorisio, T., additional, Phan, A., additional, Bergsland, E., additional, Law, L., additional, Banks, P., additional, Freiman, J., additional, Frazier, K., additional, Jackson, J., additional, Yao, J. C., additional, Kvols, L., additional, Lapuerta, P., additional, Zambrowicz, B., additional, Fleming, D., additional, and Sands, A., additional

Published
2014
Full Text
View/download PDF

73. NANETS treatment guidelines: Well-differentiated neuroendocrine tumors of the stomach and pancreas

Author

Kulke, M. (Matthew), Anthony, L.B. (Lowell), Bushnell, D.L. (David), Herder, W.W. (Wouter) de, Goldsmith, S.J. (Stanley), Klimstra, D.S. (David), Marx, S.J. (Stephen), Pasieka, J.L. (Janice), Pommier, R.F. (Rodney), Yao, J.C. (James), Jensen, R.T. (Robert), Kulke, M. (Matthew), Anthony, L.B. (Lowell), Bushnell, D.L. (David), Herder, W.W. (Wouter) de, Goldsmith, S.J. (Stanley), Klimstra, D.S. (David), Marx, S.J. (Stephen), Pasieka, J.L. (Janice), Pommier, R.F. (Rodney), Yao, J.C. (James), and Jensen, R.T. (Robert)

Abstract

Well-differentiated neuroendocrine tumors (NETs) of the stomach and pancreas represent 2 major subtypes of gastrointestinal NETs. Historically, there has been little consensus on the classification and management of patients with these tumor subtypes. We provide an overview of well-differentiated NETs of the stomach and pancreas and describe consensus guidelines for the treatment of patients with these malignancies. Copyright

Published
2010
Full Text
View/download PDF

79. A phase II, multicenter, randomized, double-blind, placebo-controlled, ascending, multidose, U.S. study of oral LX1606 (aka LX1032) in patients with refractory symptomatic carcinoid syndrome.

Author

Kulke, M., primary, O'Dorisio, T. M., additional, Phan, A. T., additional, Langdon, R. M., additional, Marek, B. J., additional, Iklaque, N., additional, Bergsland, E. K., additional, Freiman, J., additional, Frazier, K., additional, Jackson, J., additional, and Zambrowicz, B., additional

Published
2011
Full Text
View/download PDF

82. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum

Author

Walsh, K. M., primary, Choi, M., additional, Oberg, K., additional, Kulke, M. H., additional, Yao, J. C., additional, Wu, C., additional, Jurkiewicz, M., additional, Hsu, L.-I., additional, Hooshmand, S. M., additional, Hassan, M., additional, Janson, E. T., additional, Cunningham, J. L., additional, Vosburgh, E., additional, Sackler, R. S., additional, Lifton, R. P., additional, DeWan, A. T., additional, and Hoh, J., additional

Published
2010
Full Text
View/download PDF

88. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

Author

Souglakos, J, primary, Philips, J, additional, Wang, R, additional, Marwah, S, additional, Silver, M, additional, Tzardi, M, additional, Silver, J, additional, Ogino, S, additional, Hooshmand, S, additional, Kwak, E, additional, Freed, E, additional, Meyerhardt, J A, additional, Saridaki, Z, additional, Georgoulias, V, additional, Finkelstein, D, additional, Fuchs, C S, additional, Kulke, M H, additional, and Shivdasani, R A, additional

Published
2009
Full Text
View/download PDF

91. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis

Author

Bradbury, P. A., primary, Zhai, R., additional, Hopkins, J., additional, Kulke, M. H., additional, Heist, R. S., additional, Singh, S., additional, Zhou, W., additional, Ma, C., additional, Xu, W., additional, Asomaning, K., additional, Ter-Minassian, M., additional, Wang, Z., additional, Su, L., additional, Christiani, D. C., additional, and Liu, G., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results